Amycretin: What to Know About Novo Nordisk’s Investigational GLP-1 and Amylin Medicine 24th May 20266th April 2026 by Living Diabetes Editorial Team Amycretin is an investigational GLP-1 and amylin medicine from Novo Nordisk. Learn what early trials show and what remains unknown.
